D'Avino, Alessandro
 Distribuzione geografica
Continente #
EU - Europa 1.186
NA - Nord America 916
AS - Asia 213
SA - Sud America 5
AF - Africa 2
OC - Oceania 2
Totale 2.324
Nazione #
US - Stati Uniti d'America 900
DE - Germania 394
PL - Polonia 211
FR - Francia 146
SE - Svezia 142
CN - Cina 129
IT - Italia 105
UA - Ucraina 80
IN - India 38
IE - Irlanda 35
GB - Regno Unito 31
FI - Finlandia 21
SG - Singapore 20
CA - Canada 15
TR - Turchia 13
RU - Federazione Russa 7
IR - Iran 6
BE - Belgio 4
BR - Brasile 3
DK - Danimarca 3
HK - Hong Kong 3
AU - Australia 2
CL - Cile 2
KR - Corea 2
NL - Olanda 2
AT - Austria 1
EE - Estonia 1
ET - Etiopia 1
GR - Grecia 1
HR - Croazia 1
JP - Giappone 1
MM - Myanmar 1
MX - Messico 1
RO - Romania 1
TN - Tunisia 1
Totale 2.324
Città #
Kraków 210
Chandler 203
Jacksonville 67
Ashburn 64
New York 46
San Mateo 42
Redmond 37
Dublin 35
Ann Arbor 29
Milan 28
Cattolica 27
Nürnberg 26
Wilmington 26
Nanjing 25
Dearborn 24
Lawrence 18
Woodbridge 18
Houston 17
Boston 15
Singapore 14
Izmir 13
Nanchang 13
Ottawa 13
Lancaster 12
Changsha 11
Fairfield 11
Redwood City 11
Beijing 9
Shenyang 9
Kunming 8
Rome 8
Falls Church 7
Augusta 6
Chicago 6
Fremont 6
Hebei 6
Mountain View 6
Shanghai 6
Hangzhou 5
Leawood 5
Los Angeles 5
Marseille 5
Munich 5
Seattle 5
Tianjin 5
Verona 5
Bari 4
Bremen 4
Brussels 4
Cambridge 4
Guangzhou 4
Jinan 4
Kish 4
Pune 4
University Park 4
Washington 4
Boardman 3
Fuzhou 3
Modena 3
Moscow 3
Paris 3
Princeton 3
Ardabil 2
Auburn Hills 2
Busto Arsizio 2
Clearwater 2
Cupertino 2
Helsinki 2
Henderson 2
Hong Kong 2
Jiaxing 2
San Jose 2
Simi Valley 2
Toronto 2
Zhengzhou 2
Addis Ababa 1
Amsterdam 1
Andover 1
Bangalore 1
Bologna 1
Clifton 1
Downers Grove 1
Edinburgh 1
Groningen 1
Hefei 1
Lanzhou 1
London 1
Millbury 1
Monmouth Junction 1
New Orleans 1
Ningbo 1
Petriolo 1
Philadelphia 1
Phoenix 1
Phoenixville 1
Raleigh 1
San Diego 1
Sassari 1
Secunderabad 1
Sovicille 1
Totale 1.281
Nome #
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 193
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 165
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 161
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 154
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 145
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 145
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 127
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 127
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 119
Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy 109
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 106
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 102
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 99
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 98
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 86
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 79
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 78
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 72
Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area 69
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 59
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 52
Totale 2.345
Categoria #
all - tutte 7.142
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.142


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020321 76 16 17 7 33 25 16 30 26 21 38 16
2020/2021162 8 20 4 15 19 10 12 1 35 5 30 3
2021/2022245 18 18 6 20 11 19 3 44 13 28 29 36
2022/2023457 65 77 29 79 35 54 8 45 57 1 5 2
2023/2024231 12 66 4 26 14 59 10 0 3 3 25 9
2024/20254 4 0 0 0 0 0 0 0 0 0 0 0
Totale 2.345